Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Papagno

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Vaccines|July 30, 2025
An In Vitro Approach to Prime or Boost Human Antigen-Specific CD8<sup>+</sup> T Cell Responses: Applications to Vaccine StudiesHoang Oanh Nguyen, Mariela P Cabral-Piccin, Victor Appay, et al.
Experimental Gerontology|February 20, 2007
Accelerated immune senescence and HIV-1 infectionVictor Appay, Jorge R Almeida, Delphine Sauce, et al.
Journal of Immunological Methods|October 9, 2007
Cell permeabilization for the assessment of T lymphocyte polyfunctional capacityLaura Papagno, Jorge R Almeida, Elisa Nemes, et al.
European Journal of Immunology|July 14, 2025
Human Type-I Interferon Omega Holds Potent Antiviral Properties and Promotes Cytolytic CD8<sup>+</sup> T Cell ResponsesHoang Oanh Nguyen, Patricia Recordon Pinson, Marie-Line Andreola, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 10, 2019
New Insights into Lymphocyte Differentiation and Aging from Telomere Length and Telomerase Activity MeasurementsTinhinane Fali, Laura Papagno, Charles Bayard, et al.
AIDS (London, England)|December 24, 2013
The tyrosine kinase inhibitor Dasatinib blocks in-vitro HIV-1 production by primary CD4+ T cells from HIV-1 infected patientsManuela Pogliaghi, Laura Papagno, Sidonie Lambert, et al.
Scientific Reports|July 17, 2020
The TLR9 ligand CpG ODN 2006 is a poor adjuvant for the induction of de novo CD8<sup>+</sup> T-cell responses in vitroLaura Papagno, Nozomi Kuse, Anna Lissina, et al.
Antiviral Therapy|June 3, 2010
Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatmentMarta Massanella, Cristina Tural, Laura Papagno, et al.
Ebiomedicine|August 3, 2020
New chimeric TLR7/NOD2 agonist is a potent adjuvant to induce mucosal immune responsesAlice Gutjahr, Laura Papagno, Fabienne Vernejoul, et al.
Journal of Virology|July 17, 2009
Upregulation of interleukin 7 receptor alpha and programmed death 1 marks an epitope-specific CD8+ T-cell response that disappears following primary Epstein-Barr virus infectionDelphine Sauce, Martin Larsen, Rachel J M Abbott, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Vaccines|July 30, 2025
An In Vitro Approach to Prime or Boost Human Antigen-Specific CD8<sup>+</sup> T Cell Responses: Applications to Vaccine StudiesHoang Oanh Nguyen, Mariela P Cabral-Piccin, Victor Appay, et al.
Experimental Gerontology|February 20, 2007
Accelerated immune senescence and HIV-1 infectionVictor Appay, Jorge R Almeida, Delphine Sauce, et al.
Journal of Immunological Methods|October 9, 2007
Cell permeabilization for the assessment of T lymphocyte polyfunctional capacityLaura Papagno, Jorge R Almeida, Elisa Nemes, et al.
European Journal of Immunology|July 14, 2025
Human Type-I Interferon Omega Holds Potent Antiviral Properties and Promotes Cytolytic CD8<sup>+</sup> T Cell ResponsesHoang Oanh Nguyen, Patricia Recordon Pinson, Marie-Line Andreola, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 10, 2019
New Insights into Lymphocyte Differentiation and Aging from Telomere Length and Telomerase Activity MeasurementsTinhinane Fali, Laura Papagno, Charles Bayard, et al.
AIDS (London, England)|December 24, 2013
The tyrosine kinase inhibitor Dasatinib blocks in-vitro HIV-1 production by primary CD4+ T cells from HIV-1 infected patientsManuela Pogliaghi, Laura Papagno, Sidonie Lambert, et al.
Scientific Reports|July 17, 2020
The TLR9 ligand CpG ODN 2006 is a poor adjuvant for the induction of de novo CD8<sup>+</sup> T-cell responses in vitroLaura Papagno, Nozomi Kuse, Anna Lissina, et al.
Antiviral Therapy|June 3, 2010
Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatmentMarta Massanella, Cristina Tural, Laura Papagno, et al.
Ebiomedicine|August 3, 2020
New chimeric TLR7/NOD2 agonist is a potent adjuvant to induce mucosal immune responsesAlice Gutjahr, Laura Papagno, Fabienne Vernejoul, et al.
Journal of Virology|July 17, 2009
Upregulation of interleukin 7 receptor alpha and programmed death 1 marks an epitope-specific CD8+ T-cell response that disappears following primary Epstein-Barr virus infectionDelphine Sauce, Martin Larsen, Rachel J M Abbott, et al.
Pageof 4